Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Darvadstrocel · CX-601

Cell therapy (Stem-cell derived) · developed by Takeda

N/A Most advanced trial
TAK Developer
1 Registered trials

What is Darvadstrocel?

Darvadstrocel (also known as Cx601) is a cell therapy made of adipose-derived stem cells, studied for the treatment of Crohn's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CX-601
Drug type
Cell therapy (Stem-cell derived)
Therapy area
Gastroenterology
Developer
Takeda (TAK)
FDA status
Investigational, not approved in the US. Most advanced trial: N/A
UNII
31W7R94KYT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05113095 N/A Crohn's Disease Recruiting TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Crohn's Disease

More from Takeda

Follow TAK, the company behind Darvadstrocel

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.